GSK Bio

6 articles with GSK Bio

• 

  GSK's RSV Vaccine Wins Adcomm Backing One Day after Pfizer

  3/2/2023

  Wednesday, the FDA’s VRBPAC agreed that GSK's respiratory syncytial virus vaccine candidate is safe and effective in older adults. 
• 

  FDA Adcomm Clears Way for GSK's Jemperli in Rectal Cancer

  2/10/2023

  The FDA's Oncologic Drugs Advisory Committee voted 8-5 that two single-arm trials would be “sufficient to characterize the benefits and risks” of Jemperli in locally advanced rectal cancer.
• 

  Pfizer Catches Up to GSK as RSV Candidate Snags Priority Review

  12/7/2022

  In the heated race for a new respiratory syncytial virus vaccine for older adults, Pfizer gained ground on GSK after winning priority review designation for its vaccine candidate.

• AnaptysBio- and GSK-partnered immuno-oncology agent JEMPERLI (dostarlimab-gxly) meets primary endpoint in Phase 3 RUBY trial in primary advanced or recurrent endometrial cancer

  12/2/2022

  AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that GSK’s RUBY/ENGOT-EN6/GOG3031/NSGO Phase 3 trial of JEMPERLI.

• 

  Immatics Falls Victim to GSK's Receding Cell Therapy Pipeline

  11/17/2022

  GSK has pulled out of its partnership focused on developing T-cell receptor therapeutics for solid tumors with Immatics, the German biotech revealed in its Q3 financial results published Thursday.
• 

  GSK Abandons Cell Therapy Collaboration with Lyell

  10/25/2022

  GSK terminated its cell therapy pact with Lyell Immunopharma. It's opting to advance its own programs without use of Lyell’s T-cell modulating technologies that were at the center of the partnership.